Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insomnia is associated with increased risk for suicide. The Food and Drug Administration (FDA) has mandated that warnings regarding suicide be included in the prescribing information for hypnotic medications. The authors conducted a review of the evidence for and against the claim that hypnotics increase the risk of suicide. METHOD: This review focused on modern, FDA-approved hypnotics, beginning with the introduction of benzodiazepines, limiting its findings to adults. PubMed and Web of Science were searched, crossing the terms "suicide" and "suicidal" with each of the modern FDA-approved hypnotics. The FDA web site was searched for postmarketing safety reviews, and the FDA was contacted with requests to provide detailed case reports for hypnotic-related suicide deaths reported through its Adverse Event Reporting System. RESULTS: Epidemiological studies show that hypnotics are associated with an increased risk for suicide. However, none of these studies adequately controlled for depression or other psychiatric disorders that may be linked with insomnia. Suicide deaths have been reported from single-agent hypnotic overdoses. A separate concern is that benzodiazepine receptor agonist hypnotics can cause parasomnias, which in rare cases may lead to suicidal ideation or suicidal behavior in persons who were not known to be suicidal. On the other hand, ongoing research is testing whether treatment of insomnia may reduce suicidality in adults with depression. CONCLUSIONS: The review findings indicate that hypnotic medications are associated with suicidal ideation. Future studies should be designed to assess whether increases in suicidality result from CNS impairments from a given hypnotic medication or whether such medication decreases suicidality because of improvements in insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This confirms previous findings, suggesting increasing levels of suicidal ideation, suicide attempts, and suicide risk in patients administered with Z-drugs (Brower et al., 2011; MCCall et al., 2017).”
From An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions (2019) · cites this paper as MCCall et al., 2017
In the citing paper
“The impact of benzodiazepines on the risk of suicidal behaviours is unknown.8”
From Risk of suicide attempt and suicide associated with benzodiazepine: A nationwide case crossover study (2023) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Watson, W. A., Litovitz, T. L., Rodgers, G. C., Klein-Schwartz, W., Reid, N., Youniss, J., Flanagan, A., & Wruk, K. M. (2005) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2005.05.001 · Cited by 1,148
Edinger, J. D., Bonnet, M. H., Bootzin, R. R., Doghramji, K., Dorsey, C. M., Espie, C. A., Jamieson, A. O., McCall, W. V., Morin, C. M., & Stepanski, E. J. (2004) · Sleep · doi:10.1093/sleep/27.8.1567 · Cited by 1,039
Self-citationMowry, J. B., Spyker, D. A., Cantilena, L. R., McMillan, N., & Ford, M. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.987397 · Cited by 849
Ancoli‐Israel, S., & Roth, T. G. (1999) · PubMed · Cited by 776
Insomnia and daytime cognitive performance: A meta-analysis
Fortier-Brochu, É., Beaulieu-Bonneau, S., Ivers, H., & Morin, C. M. (2012) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2011.03.008 · Cited by 753 · cited 2×
“Cognitive impairment, specifically problems with decision making and executive function, are common to both insomnia and suicide;(44;45) hence further cognitive impairment at the time of peak drug effect may further tilt the balance towards suicide.”
BackgroundBronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Giffin, S. L. (2009) · Clinical Toxicology · doi:10.3109/15563650903438566 · Cited by 485
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480
Self-citationBronstein, A. C., Spyker, D. A., Cantilena, L. R., Rumack, B. H., & Dart, R. C. (2012) · Clinical Toxicology · doi:10.3109/15563650.2012.746424 · Cited by 421
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Giffin, S. L. (2010) · Clinical Toxicology · doi:10.3109/15563650.2010.543906 · Cited by 354
National Use of Prescription Medications for Insomnia: NHANES 1999-2010
Bertisch, S. M., Herzig, S. J., Winkelman, J. W., & Buettner, C. (2014) · Sleep · doi:10.5665/sleep.3410 · Cited by 305 · cited 1×
“The latter possibility has public health significance as 3% of non-institutionalized adult Americans reported using a hypnotic in the last month.(6) Up to 10% of adults in the USA use over the counter sleep aids,(7) but over the counter sleep aids have not been linked with suicide, carry no FDA warnings for suicide, a…”
Background
Research works printed but not linked: 1
- Ancoli-Israel S, 1999, Sleep, 22, S347
Cited by
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial
McCall, W. V., Benca, R. M., Rosenquist, P. B., Youssef, N. A., McCloud, L., Newman, J. C., Case, D., Rumble, M. E., Szabo, S. T., Phillips, M., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19030267 · Cited by 157
Self-citationKearns, J. C., Coppersmith, D. D. L., Santee, A. C., Insel, C., Pigeon, W. R., & Glenn, C. R. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2018.09.011 · Cited by 115
Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit
Kripke, D. F. (2016) · F1000Research · doi:10.12688/f1000research.8729.1 · Cited by 106
Palagini, L., Manni, R., Aguglia, E., Amore, M., Brugnoli, R., Bioulac, S., Bourgin, P., Micoulaud‐Franchi, J., Girardi, P., Grassi, L. G., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.688890 · Cited by 107
“In psychiatric disorders, either one of these two actions and their combination could have interesting effects in clinical practice (10, 11).”
Background
Metadata
- Authors
- McCall, W. V., Benca, R. M., Rosenquist, P. B., Riley, M. A., McCloud, L., Newman, J. C., Case, D., Rumble, M., & Krystal, A. D.
- Affiliations
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2017-01-01
- Volume
- 174
- Issue
- 1
- Pages
- 18-25
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5205566
- OpenAlex
- W2510989636
- Cited by
- 139
- References
- 44
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 12 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 21 · 2019: 14 · 2018: 29 · 2017: 6
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Mental Health (R01MH095778, R01MH095776, R01MH095780)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- hypnotics, suicide risk, insomnia, benzodiazepines, benzodiazepine receptor agonists, suicidal ideation, parasomnias, depression, FDA warning, post-marketing safety, adverse event reporting
- MeSH terms
- Suicide Prevention, Adult, Aged, Cause of Death, Dose-Response Relationship, Drug, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Middle Aged, Product Surveillance, Postmarketing, Prospective Studies, Risk, Suicide, United States, United States Food and Drug Administration, Cohort Studies, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. https://app.cochat.ai/papers/10.1176/appi.ajp.2016.16030336
- The paper
- McCall, W. V., Benca, R. M., Rosenquist, P. B., Riley, M. A., McCloud, L., Newman, J. C., Case, D., Rumble, M., & Krystal, A. D. (2017). Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2016.16030336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.